Multicenter Comparative Study of 6‐ and 10‐mm Fully Covered Self‐Expandable Metal Stents for Malignant Distal Biliary Obstruction During Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer
Journal of Hepato-Biliary-Pancreatic Sciences · 2025
DOI: 10.1002/jhbp.12157 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2025. Verfasst von Arata Sakai und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Self Expandable Metallic Stents, Cholestasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
The use of 10‐mm fully covered self‐expandable metal stents for preoperative bile duct drainage in patients with pancreatic cancer is increasing. However, these can cause complications (cholecystitis and pancreatitis) that may affect surgical outcomes. Smaller‐diameter self‐expandable metal stents may reduce these risks; however, the optimal stent size is unclear.
Methods
Patients with pancreatic cancer who underwent neoadjuvant chemotherapy and placement of either 6 or 10‐mm fully covered self‐expandable metal stents for malignant distal biliary obstruction were included. The primary outcome was the 90‐day incidence of recurrent biliary obstruction. Secondary outcomes were non‐recurrent biliary obstruction and adverse events.
Results
Fifty‐three patients were enrolled (27 and 26 patients received 6‐mm and 10‐mm self‐expandable metal stents, respectively). The 90‐day incidence of recurrent biliary obstruction of the 6‐mm group was significantly higher than that of the 10‐mm group (30.8% vs. 3.8%; p = 0.02). Stent migration occurred more frequently in the 6‐mm group (26.9% vs. 0%; p = 0.01). Although non‐recurrent biliary obstruction adverse events were less common in the 6‐mm group, the difference was not statistically significant (11.1% vs. 23.0%; p = 0.29).
Conclusions
The 10‐mm self‐expandable metal stents were more suitable for the preoperative management of pancreatic cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan.
- Division of Hepatobiliary and Pancreatic Diseases, Department of Gastroenterology, Hyogo Medical University, Nishinomiya, Hyōgo, Japan.
ORCID-Profile: Arata Sakai, Atsuhiro Masuda, Mamoru Takenaka, Hideyuki Shiomi, Shinya Kohashi
Zitieren
APA
Sakai, A., Masuda, A., Takenaka, M., Shiomi, H., Omoto, S., Yoshida, A., Nakano, R., Kawase, Y., Kohashi, S., Kodama, Y., & SMT Study Group in Japan (2025). Multicenter Comparative Study of 6‐ and 10‐mm Fully Covered Self‐Expandable Metal Stents for Malignant Distal Biliary Obstruction During Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.12157
Vancouver
Sakai A, Masuda A, Takenaka M, Shiomi H, Omoto S, Yoshida A, et al. Multicenter Comparative Study of 6‐ and 10‐mm Fully Covered Self‐Expandable Metal Stents for Malignant Distal Biliary Obstruction During Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer. Journal of Hepato-Biliary-Pancreatic Sciences. 2025. doi:10.1002/jhbp.12157
BibTeX
@article{Sakai2025,
author = {Sakai, Arata and Masuda, Atsuhiro and Takenaka, Mamoru and Shiomi, Hideyuki and Omoto, Shunsuke and Yoshida, Akihiro and Nakano, Ryota and Kawase, Yuta and Kohashi, Shinya and Kodama, Yuzo and SMT Study Group in Japan, SMT Study Group in Japan},
title = {Multicenter Comparative Study of 6‐ and 10‐mm Fully Covered Self‐Expandable Metal Stents for Malignant Distal Biliary Obstruction During Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2025},
doi = {10.1002/jhbp.12157}
}
EUVIMED